Published on May 29, 2024- TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138. https://lnkd.in/g-8KMKcY
TransCode Therapeutics, Inc.
Biotechnology Research
Newton, Massachusetts 1,728 followers
Delivering a cancer-free future
About us
TransCode's lofty goal is delivering a cancer-free future for all cancer patients. Our core belief is that cancer can be overcome through the intelligent design and efficient delivery of targeted therapeutics. Our lead therapeutic candidate, TTX-MC138, targets microRNA-10b, or miRNA-10b, considered the master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and several others. Our other preclinical programs include two solid tumor programs, TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1, or PD-L1, and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. TransCode also has three cancer agnostic programs, TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I, or RIG-I, targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. Until now, targeting biomarkers that are the primary drivers of cancer onset, progression and recurrence have been locked behind the challenge of delivery – cytosolic delivery to engage these known targets. TransCode believes it has overcome this barrier, opening the door to a broad array of cancer therapies -- a disease with the highest unmet need that affects everyone. It is through the design and optimization of this technology that TransCode has devised an elegant solution -- TTX -- a proprietary delivery platform for the transport of targeted therapeutics to cancer cells. With their world class team and know how, TransCode has a rapidly expanding platform of drug candidates designed to target a variety of tumor indications with the goal of long-term treatment survival.
- Website
-
http://www.transcodetherapeutics.com
External link for TransCode Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Newton, Massachusetts
- Type
- Public Company
- Founded
- 2016
- Specialties
- Oncology, RNA, Diagnostics, Nucleic Acid Therapeutics, Orphan Disease Designation, Metastasis, Checkpoint Inhibitor, Pattern Recognition Receptor, mRNA vaccine, and CRISPR
Locations
-
Primary
Get directions
73b Chapel St
Newton, Massachusetts 02458, US
Employees at TransCode Therapeutics, Inc.
Updates
-
TransCode Therapeutics, Inc. reposted this
🌟 Celebrating Women's History Month 🌟 This month we're highlighting trailblazing women who are making remarkable contributions in their fields. Meet Zdravka Medarova, a visionary leader in #biomedical innovation. A co-founder of TransCode Therapeutics, Inc., Zdravka’s pioneering work is revolutionizing cancer treatment. Her dedication to translating cutting-edge technology, developed during her time at Harvard Medical School, is shaping the future of nucleic-acid based therapies against cancer. 💪🔬👩🔬 Nucleic acids offer unparalleled versatility and modularity, promising highly effective drugs that could redefine cancer care. Zdravka’s leadership has propelled TransCode's lead therapeutic candidate, TTX-MC138, into early-stage clinical trials, offering hope to patients worldwide. 🌍 We honor Zdravka’s groundbreaking contributions and celebrate the relentless pursuit of innovation in healthcare. Connect with Zdravka: https://lnkd.in/gPDDdPcC #WomensHistoryMonth #Innovation #CancerResearch #BizWomenMorse #Biotech #LifeSciences #CancerTreatment #Healthcare
-
-
TransCode Therapeutics, Inc. reposted this
Zdravka Medarova, Chief Scientific Officer of Morse client TransCode Therapeutics, Inc. will present at this year’s RNA Leaders Europe Congress scheduled to take place March 12-14 in Basel, Switzerland. The conference is focused on the development of mRNA, RNAi, ASOs, oligonucleotides, vaccines, microRNAs, genome editing, wider nucleic acids and RNA targets. Dr. Medarova’s presentation, 'A First-in-Class Therapy Against Metastatic Cancer: From Pre-Clinical Testing to Early Clinical Trials', will describe work completed in support of TransCode’s ongoing Phase 0 microdose clinical study with its lead therapeutic candidate, TTX-MC138. Read more: https://lnkd.in/eYPsYVnw #RNAleaders #RNA #cancerresearch #mRNA
-
-
Conference Producer at Hanson Wade | First Class MSci Chemistry Graduate from Imperial College London
I had the pleasure of speaking with Zdravka Medarova, Founder and Chief Scientific Officer at TransCode Therapeutics, Inc., who is set to share her invaluable insights at the upcoming 5th RNAi Based Therapeutics Summit, February 13-15, Boston. “RNAi really represents a turning point in the way we treat disease. With small molecules and monoclonal antibodies, at least in the field of cancer, only 20% of known drug targets are actually druggable. However, with RNAi, essentially any disease-causing gene becomes druggable.” If you are eager to dive deeper into Zdravka’s thoughts, take a look at her presentation session on the agenda here: https://ter.li/qfawcn
-
Check out our CSO, Zdravka Medarova, in this exclusive speaker interview as we gear up for the RNAi-Based Therapeutics Summit.
-
-
TransCode Therapeutics, Inc. reposted this
New speaker Announcement! We're excited to announce the latest speakers to join RNA Leaders Europe to help accelerate the innovation and commercialization of RNA therapeutics and vaccines! Zdravka Medarova - Founder & CTO, TransCode Therapeutics, Inc. 🌐 Presenting: Translating Targeting Metastatic Cancer with Oligos Jacqueline Fok - Investment VP, Softbank Vision Fund 🎤 Keynote Panel: Investing in RNA Medicines and Technologies Tomaž Einfalt - Principle Investigator II / Project Team Lead xRNA, Novartis 🔄 Round Table Host: mRNA stability during delivery Covadonga Paneda - COO, Altamira Therapeutics 💡 Presenting: Targeting Inflamed or Cancerous Tissues via Novel Peptide Delivery Sujin Lee - Professor, Emory University 📊 Presenting: Developing a mRNA Respiratory Vaccine Phil Challis - VP Product Development, etherna 🗣️ Leading Discussion: Building Quality Processes in RNA Therapeutics 📆 Save the Date: 13-14 March 2024 📍 Congress Center Basel, Basel, Switzerland Don't miss the chance to network with those shaping the future of RNA. Review the full agenda at: https://lnkd.in/dzfJxf-z #RNALeaders #RNA #Oligos #mRNA
-